Bond.az White LogoBond.az Black Logo

Goldman Sachs Raises Kinetik Price Target to $54

Goldman Sachs raises Kinetik price target to $54 from $48, citing marketing gains and positive outlook. Maintains Buy rating.

Aria Wright
ByAria Wright- Senior Editor
|
0

Goldman Sachs raised its price target on Kinetik Holdings (NYSE:KNTK) to $54 from $48, maintaining a Buy rating. The stock trades at $51.27, just below its 52-week high of $51.51, with a 60% gain over six months.

The firm updated estimates after Q1 2026 earnings modestly beat expectations. Stronger marketing gains offset lower Pipeline EBITDA. The PEG ratio stands at 0.14, suggesting attractive valuation.

Kinetik expects higher curtailments averaging ~220 mmcf/d for the rest of 2026, up from ~100 mmcf/d. It maintains 2026 EBITDA guidance of $950M-$1.05B.

Goldman Sachs cut EBITDA estimate to $1,023M from $1,063M. Kinetik can mitigate downside via Gulf Coast FT exposure and optimization. The firm remains above consensus on 2027-2028 EBITDA.

More News
Yesterday / 20:21
|
381

RBC Capital hikes Dominion Resources price target

RBC Capital raises Dominion price target to $72 on NextEra deal. Sector Perform rating maintained with 7% arbitrage spread.

0
Yesterday / 20:20
|
884

BofA raises Candel price target to $9

BofA raises Candel price target to $9 after 39% improvement in prostate cancer survival data.

0
Yesterday / 18:11
|
808

Roblox rebounds on user growth, Needham says

Needham reiterates Roblox Buy rating amid user growth rebound. Stock has 27% upside to $60 target.

0
Yesterday / 17:51
|
287

US Tiger Securities Boosts Baidu Price Target on AI

US Tiger Securities raised Baidu price target to $160 on AI growth. AI revenue now exceeds half of business.

0
Yesterday / 15:50
|
224

AMAT and LRCX stocks defended by Lynx

Lynx Equity defends AMAT and LRCX stocks with bullish price targets of $540 and $325 respectively.

0
Yesterday / 14:45
|
827

DA Davidson Maintains Brunswick Stock Neutral

DA Davidson reaffirms Neutral rating on Brunswick with $76 target. Premium brands strong, value brands weak. Q1 2026 results beat estimates.

0
Yesterday / 14:43
|
834

D.A. Davidson Reaffirms Aebi Schmidt on Strong Orders

D.A. Davidson reaffirms Buy rating on Aebi Schmidt with $15 target. Strong order backlog up 23%. Revenue beats expectations. Get details on Bond.az.

0
Yesterday / 13:32
|
366

Freedom Broker Upgrades Kinross Gold Rating

Freedom Broker upgrades Kinross Gold to Buy with $38 target. Strong cash flow and record margins drive the upgrade.

0
Yesterday / 13:01
|
960

JPMorgan Reiterates Five Below Stock Rating with $306 Target

JPMorgan reiterates Overweight rating on Five Below with $306 price target, implying 43% upside potential.

0
Yesterday / 11:44
|
685

Elmet Stock Gets Overweight Rating

Cantor Fitzgerald starts Elmet Group with Overweight rating and $20 target. Defense and reshoring trends drive outlook.

0
Yesterday / 11:25
|
722

Truist Starts Arcus Biosciences at Buy on RCC Potential

Truist Securities initiates Arcus Biosciences with Buy rating and $35 price target, citing casdatifan's potential in renal cell carcinoma and immunology pipeline.

0
Yesterday / 11:24
|
728

Revolution stock buy rating from Truist

Truist Securities gives Revolution Medicines a buy rating with a $179 price target. Daraxon's potential and company outlook.

0
...